Global landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome - PubMed
5 hours ago
- #clinical trials
- #irritable bowel syndrome
- #gut microbiota
- Systematic analysis of global interventional clinical trials on gut microbiota modulation (GMM) therapies for irritable bowel syndrome (IBS).
- Asia was the most active region, with trials peaking in 2021, dominated by Phase II (44.3%) and IV (33.3%).
- Probiotics (single-strain: Lactobacillus/Bifidobacterium; multi-strain: Lactobacillus + Bifidobacterium) were the most studied, followed by fecal microbiota transplantation (FMT).
- IBS-D (49.6%) was the main subtype, with probiotics most frequently studied for both IBS-D and IBS-C, FMT for IBS-D, and prebiotics for IBS-C.
- GMM therapies for IBS are relatively mature, with personalized therapies and emerging treatments like Akkermansia muciniphila expected to advance precision medicine.